Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths

• Váldodahkkit: Peter A. Kropp (Dahkki), Rosemary Bauer (Dahkki), Isabella Zafra (Dahkki), Carina Graham (Dahkki), Andy Golden (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: The Company of Biologists, 2021-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Although nearly 10% of Americans suffer from a rare disease, clinical progress in individual rare diseases is severely compromised by lack of attention and research resources compared to common diseases. It is thus imperative to investigate these diseases at their most basic level to build a foundat...